First-in-Human Dose Escalation Study of XMT-1536 in Cancers Likely to Express NaPi2b

Clinical trial NCT06517433 · COMPLETED

Trial details

NCT number: NCT06517433
Sponsor: Mersana Therapeutics
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Platinum Resistant Ovarian Cancer Non Small Cell Lung Cancer Metastatic

Start date: 2017-12-12
Primary completion: 2021-07-09
Enrollment: 62

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.